Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update on Investigational Drugs for Alzheimer’s Disease

10/24/2019

 
We heard much about drugs in development to treat or delay the onset of Alzheimer’s disease during 2018. There are twenty-five investigational drugs targeting Alzheimer's disease currently in the Pharmaceutical Pipeline Tracker. None of the drugs have PDUFA dates at this time although there are five drugs with FDA Priority Designations.

Progress was anticipated in the treatment of the disease this year. But the newswires have become largely radio silent. Following is an example of what we did hear.

In March Biogen announced that an interim analysis by an independent committee of two Phase III trials involving patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. The interim futility analysis was based on data from 1,748 patients and found a low likelihood that aducanumab would improve or slow cognition in Alzheimer’s patients, so Biogen discontinued both trials in March 2019. 

In the meantime, Biogen analyzed addition data from 3,285 patients, of which 2,066 had completed the full 18 months of treatment and found a reduction in cognition reduction compared to placebo in the one of the trials’ data. The benefit was primarily from an analysis of an expanded cohort of patients which found a reduction in the decline in cognition with the higher dose of aducanumab as demonstrated by improvements over 78 weeks in 547 patients compared to placebo in CDR-SB (23%), MMSE (15%), ADAS-Cog 13 (27%) and ADCS-ADL-MCI (40%). The expanded cohort of high dose patients did not demonstrate an improvement compared to placebo. Biogen will offer patients enrolled in the two trials continued access to aducanumab, along with the long-term extension study for a Phase 1b study, and safety study of the data from one of the previous Trials. Biogen plans to file a BLA for aducanumab in early 2020.

Ten trials of investigational drugs targeting Alzheimer’s have been discontinued. Of those attempts still in progress a number of pathways are under investigation. For example: monoclonal antibodies, BACE Inhibitors, amyloid beta protein inhibitors, caprilic triglycerides, and beta ameloid reduction. One of the companies involved in the research has gone out of business. Another has no ongoing US trials.

Most of the ongoing Phase III trials are slated to deliver results no earlier than late 2020.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.